title: Epigenetic targeting in pancreatic cancer.
abstract: The prognosis of pancreatic cancer patients is very poor, with a 5-year survival of less than 6%. Therefore, there is an urgent need for new therapeutic options in pancreatic cancer. In the past years it became evident that deregulation of epigenetic mechanisms plays an important role in pancreatic carcinogenesis. This review focuses on the exploitation of drugs that alter histone modifications, DNA methylation and microRNA expression as options for the treatment of pancreatic cancer.
authors.affiliation: Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Department of Urology 267, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Jasmijn.vanKampen@radboudumc.nl.
authors.forename: Jasmijn G M
authors.initials: JG
authors.lastname: van Kampen
authors.affiliation: Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Monica.vanZanten@radboudumc.nl.
authors.forename: Monica A J
authors.initials: MA
authors.lastname: Marijnissen-van Zanten
authors.affiliation: Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Femke.Doubrava-Simmer@radboudumc.nl.
authors.forename: Femke
authors.initials: F
authors.lastname: Simmer
authors.affiliation: Department of Medical Oncology 452, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Winette.vanderGraaf@radboudumc.nl.
authors.forename: Winette T A
authors.initials: WT
authors.lastname: van der Graaf
authors.affiliation: Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands; Department of Human Genetics 855, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Marjolijn.Ligtenberg@radboudumc.nl.
authors.forename: Marjolijn J L
authors.initials: MJ
authors.lastname: Ligtenberg
authors.affiliation: Department of Pathology 824, Radboud University Medical Center, PO Box 9101, 6500 HB Nijmegen, The Netherlands. Electronic address: Iris.Nagtegaal@radboudumc.nl.
authors.forename: Iris D
authors.initials: ID
authors.lastname: Nagtegaal
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D019175:DNA Methylation / Q000187:drug effects* / Q000235:genetics; D044127:Epigenesis, Genetic / Q000187:drug effects* / Q000235:genetics; D005260:Female; D005544:Forecasting; D015972:Gene Expression Regulation, Neoplastic; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000187:drug effects / Q000235:genetics; D058990:Molecular Targeted Therapy / Q000379:methods / Q000639:trends*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D016896:Treatment Outcome; D059016:Tumor Microenvironment / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D035683:MicroRNAs; D000076983:Histone Methyltransferases; D011495:Histone-Lysine N-Methyltransferase
keywords: DNA methyltransferase inhibitor; Epigenetics; Histone deacetylase inhibitor; Histone methyltransferase inhibitor; MicroRNA; Pancreatic cancer; Therapy